ArticleNature medicine2026
AI framework for multidisease detection via retinal imaging.
Article in Nature medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- Editorial for the Special Issue "Applications of Biomedical Imaging and Sensing Technologies in Disease Diagnosis".Sensors (Basel, Switzerland) · 2026Article
- Comparison of Cox Proportional Hazards Regression and Multiple Logistic Regression Models for Identifying Factors Associated With Mortality Among Children With Retinoblastoma in Malaysia: A Retrospective Cohort Study.Health science reports · 2026Article
- Spatial multi-omics unveils sphingolipid metabolic reprogramming within the retinal pathological niche.iMeta · 2026Article
- The positive correlation between the progressive photoreceptor damage and the increased macular leakage indicating the severity of diabetic retinopathy.Journal of diabetes investigation · 2026Article
- Macular Ganglion Cell-Inner Plexiform Layer (GCIPL) Thickness and Thinning Patterns for Differentiating Glaucomatous and Non-Glaucomatous Optic Neuropathy: A Prospective Comparative Study.Clinical ophthalmology (Auckland, N.Z.) · 2026Article
- Endocrinology concepts for diabetic retinopathy care: bridging systemic metabolic control with retinal disease management and patient education.Frontiers in medicine · 2026Review
- Serum Albumin as a Marker of Microvascular Burden in Diabetic Retinopathy: Mediation by Diabetic Nephropathy in Uncontrolled Diabetes.Journal of ophthalmology · 2026Article
- Editorial: Imaging in the diagnosis and treatment of eye diseases.Frontiers in ophthalmology · 2026Article
- Case Report: Persistent fetal vasculature associated with lenticular coloboma.Frontiers in medicine · 2026Article
- Patient-specific finite element analysis of orbital biomechanical responses to malpositioned self-inflating hydrogel implants in congenital microphthalmia.Frontiers in medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
27 authors.
Funding
Abstract
The rising burden of endocrine and metabolic diseases demands scalable and accessible screening tools. Here we developed Reti-Pioneer, a multitask retinal imaging framework that integrates quality-aware modules with pre-trained foundation models for efficient, multidisease detection. In general, the framework was developed using 107,730 color fundus photographs from both community-based and hospital-based cohorts and achieved area under the receiver operating characteristic curve values on internal test data of 0.833 (95% confidence interval 0.810-0.856) for type 2 diabetes mellitus, 0.832 (0.799-0.866) for gout, 0.787 (0.742-0.833) for osteoporosis, 0.740 (0.726-0.755) for hypertension, 0.736 (0.721-0.751) for hyperlipidemia and 0.699 (0.667-0.730) for thyroid disease. The framework generalized well to six external cohorts from both resource-limited and high-resource settings, and showed biological interpretability via plasma proteomic correlations. In a primary care silent trial, it completed screening in 30.6 ± 6.0 s per case, notably faster than standard laboratory workflows. A subsequent clinical pilot for type 2 diabetes mellitus yielded an area under the receiver operating characteristic curve of 0.776 (0.710-0.842) and negative predictive value of 0.966 (0.946-0.983), surpassing the Finnish Diabetes Risk Score, with high acceptance from clinicians and patients. Overall, Reti-Pioneer could provide a translatable, low-cost pathway from oculomics to actionable clinical screening.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.